These results are consistent with data showing that macrophage-mediated immunosuppression is a consequence of PARPi treatment in triple-negative breast cancer; targeting immunosuppressive macrophages overcomes PARPi resistance in BRCA1-associated triple-negative breast cancer (43). This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.